Department of Medicine, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, Norfolk NR4 7UY, UK; Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK.
Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK.
Clin Med (Lond). 2024 Nov;24(6):100249. doi: 10.1016/j.clinme.2024.100249. Epub 2024 Oct 4.
Corticosteroids raise blood glucose concentrations; however, it remains unknown which form of administration, oral or intravenous, is associated with the greatest degree of blood glucose rise in hospitalised patients. Furthermore, it is not known whether the pattern of the associated hyperglycaemia throughout the day differs depending on the route of administration.
This was a single centre retrospective study of 384 adult inpatients receiving oral or intravenous hydrocortisone and dexamethasone. Data on capillary glucose concentrations and time taken over 7 days were collected. A mixed model for repeated measures was applied to compare changes in glucose concentration over time for oral and intravenous corticosteroids. An auto-regressive covariance structure was employed to model correlations between repeated measurements. This was adjusted for age, sex, pre-admission diabetes, and/or pre-admission corticosteroid status.
No significant difference was found between oral and intravenous hydrocortisone on day 1 or across all 7 days (mean difference 0.17 mmol/L (-1.39, 1.75), p = 0.827, and mean difference 0.20 mmol/L (-0.61, 1.01), p = 0.639 respectively). There were no differences in mean glucose concentrations between those on oral or intravenous dexamethasone on day 1 or across all 7 days (mean difference 0.41 mmol/L (-0.55, 1.38), p = 0.404 and mean difference -0.09 mmol/L (-1.05,0.87), p = 0.855, respectively).
This study found that oral and intravenous administration of hydrocortisone and dexamethasone do not have a significantly differing impact on blood glucose levels. Capillary glucose monitoring is strongly recommended in all individuals who are on either oral or intravenous corticosteroids.
皮质类固醇会升高血糖浓度;然而,目前尚不清楚哪种给药方式,即口服或静脉内,与住院患者血糖升高程度相关性最大。此外,尚不清楚全天血糖升高的模式是否因给药途径而异。
这是一项对 384 名接受口服或静脉内氢化可的松和地塞米松治疗的成年住院患者的单中心回顾性研究。收集了 7 天内毛细血管血糖浓度和时间的数据。应用重复测量混合模型比较口服和静脉内皮质类固醇治疗期间血糖浓度随时间的变化。采用自回归协方差结构对重复测量之间的相关性进行建模。这是针对年龄、性别、入院前糖尿病和/或入院前皮质类固醇状态进行调整的。
在第 1 天或所有 7 天内,口服和静脉内氢化可的松之间没有发现显著差异(平均差异 0.17mmol/L(-1.39,1.75),p=0.827,和平均差异 0.20mmol/L(-0.61,1.01),p=0.639)。在第 1 天或所有 7 天内,口服和静脉内地塞米松的患者之间,平均血糖浓度没有差异(平均差异 0.41mmol/L(-0.55,1.38),p=0.404 和平均差异 -0.09mmol/L(-1.05,0.87),p=0.855)。
本研究发现,口服和静脉内给予氢化可的松和地塞米松对血糖水平没有显著不同的影响。建议所有接受口服或静脉内皮质类固醇治疗的患者都要进行毛细血管血糖监测。